Micro Medical Solutions Strengthens Leadership with New Board Appointments for Future Growth

Micro Medical Solutions Expands Board of Directors

Micro Medical Solutions (MMS), a pioneering force in the medical device sector focused on enhancing outcomes for patients suffering from Critical Limb Threatening Ischemia (CLTI), has announced the additions of Vince Burgess and John Dahldorf to its Board of Directors. This strategic move aims to fortify MMS’s leadership team as they gear up for the commercialization of their innovative MicroStent™ technology.

Leadership Enhancements

The inclusion of Burgess and Dahldorf brings a wealth of experience to the MMS Board, already headed by Chairman and CEO George Quinoy and board member Dr. Ron Solar. "We are thrilled to welcome Vince and John to the MMS Board," said Quinoy. Their combined expertise in scaling medical device companies and managing public operations will be crucial as MMS progresses through the FDA review process and prepares for market launch.

Vince Burgess, who served as President, CEO, and Director at Acutus Medical, Inc. from 2017 to 2022, carries a robust background with him. He is a former Venture Partner at OrbiMed Advisors, a global healthcare investment firm, and was a founding executive at Volcano Corporation. His tenure at Volcano saw him lead marketing and business development from 2002 to 2010. Currently, he is a board member for various organizations, including Tela Bio, Inc., and has previously held positions with companies such as NeuroPace and CardiAQ. Burgess holds a B.S. in Business Administration from the University of Southern California and an M.B.A. from UCLA.

John Dahldorf complements this leadership structure with over 25 years of experience in finance and accounting within the healthcare sector. He currently occupies the role of Chief Financial Officer at Q'Apel Medical, Inc., while also serving as a board member for Hyperfine, Inc. His past experience includes significant roles as CFO for Volcano Corporation, where he played a pivotal role in its acquisition by Royal Philips, and for several other companies like Digirad Corporation and Acutus Medical. Dahldorf earned both his B.S. in Finance and M.B.A. from Western Illinois University.

Dr. Ron Solar, another board member, highlighted the invaluable contributions Burgess and Dahldorf bring regarding innovation and commercialization strategies. Their leadership will undoubtedly enhance MMS's capacity to execute plans as the company approaches FDA approval and market readiness.

MicroStent™ Technology Overview

The MicroStent™, currently under Premarket Approval (PMA) review and recognized with the FDA Breakthrough Device Designation, is poised to make a significant impact in improving blood circulation, facilitating wound healing, and minimizing amputation risks for patients afflicted with CLTI. Given the increasing incidence of diabetes and an aging global population, the demand for such innovative medical solutions has never been more pressing.

About Micro Medical Solutions

Micro Medical Solutions is at the forefront of developing cutting-edge technology to address the critical unmet needs in below-the-knee (BTK) arterial disease. As healthcare evolves, the company is committed to safeguarding the well-being of patients who are at heightened risk of amputation, underpinning their growth strategy with significant clinical demand and regulatory progress.

For additional information, visit www.micromedicalsolutions.net.